Surufatinib plus trans arterial embolisation (TAE) vs. surufatinib monotherapy in neuroendocrine tumour with liver metastasis: Updated results from the prospective, randomised, controlled trial

#4393

Introduction: The liver is the main metastasis site for NETs. Surufatinib (SUR), an oral TKI, is standard therapy for advanced NETs. TAE is the primary local intervention for unresectable hepatic NETs.

Aim(s): This study aims to evaluate the efficacy and safety of SUR plus TAE versus SUR monotherapy in patients (pts) with hepatic metastases from NETs.

Materials and methods: This study is a prospective, randomised, controlled trial for pts (≥18 years) with liver metastatic NETs (Grade 1 or 2), and measurable hepatic lesions. 123 participants with ECOG 0 to 2 are enrolled, randomised 1:1 to receive SUR (300 mg daily) plus TAE, or SUR alone. The primary endpoint was PFS, with secondary endpoints including intrahepatic response rate (iHRR), ORR, DCR, OS and safety.

Conference:

Presenting Author: Cao D

Authors: Cao D, Li X, You X, Li R, Xiang J,

Keywords: NET, Liver metastasis, Surufatinib, TAE,